Search This Blog

Tuesday, August 4, 2020

Amarin EPS beats by $0.11, misses on revenue

Amarin (NASDAQ:AMRN): Q2 Non-GAAP EPS of $0.04 beats by $0.11; GAAP EPS of $0.01 beats by $0.09.
Revenue of $135.32M (+34.3% Y/Y) misses by $14.16M.
Normalized prescriptions for VASCEPA increased by ~44% in Q2 compared to 47% in Q2 2019, based on data from Symphony Health and IQVIA, respectively.
Press Release

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)